Mannopyranoside Glycolipids Inhibit Mycobacterial and Biofilm Growth and Potentiate Isoniazid Inhibition Activities in M. smegmatis. (26th June 2019)

• Record Type: Journal Article
• Authors: Mahapa, Avisek; Samanta, Gopal Ch; Maiti, Krishnagopal; Chatterji, Dipankar; Jayaraman, Narayanaswamy
• Is Part Of: Chembiochem. Volume 20:Number 15(2019)
• Page Start: 1966
• Page End: 1976
• Publication Date: 2019-06-26
• Subjects: antibiotics -- biofilms -- glycolipids -- inhibitors -- mycobacteria; Biochemistry -- Periodicals; Molecular biology -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1002/cbic.201900040
• Languages: English
• ISSNs: 1439-4227

Abstract

Abstract: Lipomannan and lipoarabinomannan are integral components of the mycobacterial cell wall. Earlier studies demonstrated that synthetic arabinan and arabinomannan glycolipids acted as inhibitors of mycobacterial growth, in addition to exhibiting inhibitory activities of mycobacterial biofilm. Herein, it is demonstrated that synthetic mannan glycolipids are better inhibitors of mycobacterial growth, whereas lipoarabinomannan has a higher inhibition efficiency to biofilm. Syntheses of mannan glycolipids with a graded number of mannan moieties and an arabinomannan glycolipid are conducted by chemical methods and subsequent mycobacterial growth and biofilm inhibition studies are conducted on Mycobacterium smegmatis . Growth inhibition of (73±3) % is observed with a mannose trisaccharide containing a glycolipid, whereas this glycolipid did not promote biofilm inhibition activity better than that of arabinomannan glycolipid. The antibiotic supplementation activities of glycolipids on growth and biofilm inhibitions are evaluated. Increases in growth and biofilm inhibitions are observed if the antibiotic is supplemented with glycolipids, which leads to a significant reduction of inhibition concentrations of the antibiotic. Abstract : Stunted by sugar : Lipomannan‐based synthetic glycolipids exhibit higher inhibition efficiencies to mycobacterial growth, in preference to biofilm inhibition. A two‐ and threefold increase in inhibition potency is observed if the antibiotic isoniazid is supplemented with synthetic lipomannan glycolipids, thereby reducing the concentration of antibiotic required to inhibit mycobacterial growth and biofilm phases.